← Back to Search

Probiotics

Probiotics for Obese Asthmatics with Insulin Resistance

N/A
Waitlist Available
Led By Jessy Deshane, PhD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 18 years
All patients will be obese asthmatics with a body mass index >30 and insulin resistance >5
Must not have
Inability to understand study procedures and/or provide informed consent
Comorbid lung diseases other than asthma
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks

Summary

This trial will test if oral probiotics help improve asthma symptoms in obese insulin resistant people.

Who is the study for?
This trial is for obese adults over 18 with asthma and insulin resistance. Participants must have a BMI >30, stable asthma without medication changes for 3 months, and an insulin resistance score >5. It's not open to pregnant individuals or those who can't consent, have had recent severe asthma attacks or other lung diseases.
What is being tested?
The study tests if oral probiotics can change the airway microbiome/metabolome in these patients, reduce leptin and insulin resistance levels, lead to weight loss, and improve asthma outcomes compared to a placebo.
What are the potential side effects?
While specific side effects are not listed here, probiotics are generally considered safe but may cause digestive discomfort such as gas or bloating in some people.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I am obese with a BMI over 30 and have insulin resistance greater than 5.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I understand the study procedures and can give informed consent.
Select...
I have a lung condition that is not asthma.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Determine if microbiome/metabolome changes in probiotics group correlates with changes in asthma biomarkers and improved clinical outcomes compared to placebo in obese insulin resistant asthmatics
Determine if modulation of leptin levels and insulin sensitivity by probiotics administration correlates with airway metabolome alterations and weight loss in obese insulin resistant asthmatics
Determine if probiotic administration modulates airway microbiome/metabolome in obese insulin resistant asthmatics

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ProbioticExperimental Treatment1 Intervention
Subjects will receive a probiotic supplement to take by mouth daily.
Group II: PlaceboPlacebo Group1 Intervention
Subjects will receive a placebo to take by mouth daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Probiotic
2013
Completed Phase 4
~3570

Find a Location

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,642 Previous Clinical Trials
2,332,549 Total Patients Enrolled
16 Trials studying Insulin Resistance
1,137 Patients Enrolled for Insulin Resistance
American Lung AssociationOTHER
31 Previous Clinical Trials
10,953 Total Patients Enrolled
Jessy Deshane, PhDPrincipal InvestigatorUniversity of Alabama at Birmingham

Media Library

Probiotic (Probiotics) Clinical Trial Eligibility Overview. Trial Name: NCT05949255 — N/A
Insulin Resistance Research Study Groups: Probiotic, Placebo
Insulin Resistance Clinical Trial 2023: Probiotic Highlights & Side Effects. Trial Name: NCT05949255 — N/A
Probiotic (Probiotics) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05949255 — N/A
~5 spots leftby Mar 2025